Agents in development for type 2 diabetes.

被引：1
|
作者：
Jarvis B. [1 ]
Elkinson S. [1 ]
机构：
[1] Adis International, Auckland
来源：
Drugs in R & D | 1999年 / 2卷 / 2期
关键词：
Adis International Limited; Ornithine; Acarbose; Insulin Glargine; Troglitazone;
D O I：
10.2165/00126839-199902020-00002
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：95 / 99
页数：4
相关论文
共 50 条
  • [31] MIF knockout mice are resistant to the development of type 1 diabetes.
    Al-Abed, Y
    Cvetkovic, I
    Miljkovic, D
    Metz, C
    Nicoletti, F
    Stosic-Grujicic, S
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U218 - U218
  • [32] Efficiency at 6 and 12 months of the association of external pump and oral hypoglycemic agents in type 2 diabetes.
    Labrousse, F
    Cazals, L
    Tauber, JP
    Hanaire-Broutin, H
    DIABETOLOGIA, 2000, 43 : A206 - A206
  • [33] Long-term efficacy of the combination of external pump and oral hypoglycemic agents in Type 2 diabetes.
    Labrousse, F
    Cazals, L
    Hanaire-Broutin, H
    DIABETOLOGIA, 2002, 45 : A263 - A263
  • [34] Exercise capacity is abnormal in youth with type 2 diabetes.
    Nadeau, K. J.
    Ehlers, L. B.
    Zeitler, P. S.
    Draznin, B.
    Regensteiner, J. G.
    Reusch, J. E. B.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2007, 55 (01) : S125 - S125
  • [35] Megatrials in type 2 diabetes. From excitement to frustration?
    Del Prato, S.
    DIABETOLOGIA, 2009, 52 (07) : 1219 - 1226
  • [36] Avandia™ -: From molecule to market for type 2 diabetes.
    Haigh, D
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 223 : A110 - A110
  • [37] The state of oral mucosa in patients with type 2 diabetes.
    Shnaider, S. A.
    Skyba, V. Ya
    Skyba, O., V
    Babenya, H. O.
    Varzhapetian, S. D.
    MEDICNI PERSPEKTIVI, 2020, 25 (03): : 153 - 160
  • [38] Shared genetic aetiology of osteoarthritis and type 2 diabetes.
    Arruda, Ana Luiza de Santana Villasboas
    Hartley, April
    Hatzikotoulas, Konstantinos
    Rayner, William
    Barysenka, Andrei
    Katsoula, Georgia
    Smith, George Davey
    Morris, Andrew
    Zeggini, Eleftheria
    HUMAN HEREDITY, 2022, VOL. (SUPPL 1) : 6 - 7
  • [39] Split proinsulin as a risk factor for type 2 diabetes.
    Zethelius, B
    Lithell, H
    Hales, CN
    Berne, C
    DIABETOLOGIA, 1998, 41 : A71 - A71
  • [40] Glucagon receptor antagonists for the treatment of type 2 diabetes.
    Handlon, AL
    Akwabi-ameyaw, A
    Brown, K
    De Anda, F
    Drewry, D
    Fang, J
    Irsula, O
    Li, G
    Linn, JA
    Milliken, NO
    Ramanjulu, J
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U31 - U31
12345